1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Weiss, M.A.
Hua, Q.X.
Chu, Y.C.
Jia, W.
Philips, N.F.
Wang, R.Y.
Katsoyannis, P.G.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
J.Biol.Chem.
JBCHA3
0071
0021-9258
277
43443
43453
10.1074/jbc.M206107200
12196530
Mechanism of insulin chain combination. Asymmetric roles of A-chain alpha-helices in disulfide pairing
2002
10.2210/pdb1lkq/pdb
pdb_00001lkq
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
INSULIN A CHAIN (RESIDUES 90-110)
2285.513
INSULIN
I2G,V3G
1
syn
polymer
INSULIN B CHAIN (RESIDUES 25-54)
3410.894
INSULIN
H10D,P28K,K29P
1
syn
polymer
no
no
GGGEQCCTSICSLYQLENYCN
GGGEQCCTSICSLYQLENYCN
A
polypeptide(L)
no
no
FVNQHLCGSDLVEALYLVCGERGFFYTKPT
FVNQHLCGSDLVEALYLVCGERGFFYTKPT
B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
database_2
pdbx_struct_assembly
pdbx_struct_oper_list
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
1
0
2002-05-22
1
1
2008-04-28
1
2
2011-07-13
1
3
2021-10-27
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_struct_ref_seq_dif.details
RCSB
Y
RCSB
2002-04-25
REL
REL
THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SAPIENS (HUMAN).
sample
THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF THE PEPTIDE IS NATURALLY FOUND IN HOMO SAPIENS (HUMAN).
sample
THIS STRUCTURE WAS DETERMINED USING STANDARD 2D HOMONUCLEAR TECHNIQUES.
structures with the lowest energy
35
20
2D NOESY
TOCSY
7.00
AMBIENT
298.00
K
THE STRUCTURE IS BASED ON A TOTAL OF 390 RESTRAINTS, 325 ARE NOE-DERIVED DISTANCE CONSTRAINTS, 31 DIHEDRAL ANGLE RESTRAINTS, 34 DISTANCE RESTRAINTS FROM HYDROGEN BONDS.
DISTANCE GEOMETRY AND SIMULATED ANNEALING
1
1.0 MM GLYA2,A3-DKP- INSULIN; 90% H2O/10% D2O;
BRUNGER (X-PLOR), MOLECULAR SIMULATIONS INC. (DGII)
refinement
X-PLOR 3.85, DGII INSIGHTII
2000
structure solution
VNMR
6.1B
600
Varian
INOVA
GLY
1
n
1
GLY
1
A
GLY
2
n
2
GLY
2
A
GLY
3
n
3
GLY
3
A
GLU
4
n
4
GLU
4
A
GLN
5
n
5
GLN
5
A
CYS
6
n
6
CYS
6
A
CYS
7
n
7
CYS
7
A
THR
8
n
8
THR
8
A
SER
9
n
9
SER
9
A
ILE
10
n
10
ILE
10
A
CYS
11
n
11
CYS
11
A
SER
12
n
12
SER
12
A
LEU
13
n
13
LEU
13
A
TYR
14
n
14
TYR
14
A
GLN
15
n
15
GLN
15
A
LEU
16
n
16
LEU
16
A
GLU
17
n
17
GLU
17
A
ASN
18
n
18
ASN
18
A
TYR
19
n
19
TYR
19
A
CYS
20
n
20
CYS
20
A
ASN
21
n
21
ASN
21
A
PHE
1
n
1
PHE
1
B
VAL
2
n
2
VAL
2
B
ASN
3
n
3
ASN
3
B
GLN
4
n
4
GLN
4
B
HIS
5
n
5
HIS
5
B
LEU
6
n
6
LEU
6
B
CYS
7
n
7
CYS
7
B
GLY
8
n
8
GLY
8
B
SER
9
n
9
SER
9
B
ASP
10
n
10
ASP
10
B
LEU
11
n
11
LEU
11
B
VAL
12
n
12
VAL
12
B
GLU
13
n
13
GLU
13
B
ALA
14
n
14
ALA
14
B
LEU
15
n
15
LEU
15
B
TYR
16
n
16
TYR
16
B
LEU
17
n
17
LEU
17
B
VAL
18
n
18
VAL
18
B
CYS
19
n
19
CYS
19
B
GLY
20
n
20
GLY
20
B
GLU
21
n
21
GLU
21
B
ARG
22
n
22
ARG
22
B
GLY
23
n
23
GLY
23
B
PHE
24
n
24
PHE
24
B
PHE
25
n
25
PHE
25
B
TYR
26
n
26
TYR
26
B
THR
27
n
27
THR
27
B
LYS
28
n
28
LYS
28
B
PRO
29
n
29
PRO
29
B
THR
30
n
30
THR
30
B
author_defined_assembly
2
dimeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
2
B
B
O
H
VAL
TYR
12
16
1.45
3
B
B
O
H
CYS
GLU
19
21
1.54
4
B
B
O
H
VAL
TYR
12
16
1.55
6
A
A
O
H
SER
LEU
12
16
1.57
8
B
B
O
H
VAL
TYR
12
16
1.44
9
B
B
O
H
VAL
TYR
12
16
1.45
9
A
A
H
OE1
SER
GLN
12
15
1.51
11
B
B
O
H
CYS
GLU
19
21
1.56
14
B
B
O
H
CYS
LEU
7
11
1.59
17
B
B
O
H
SER
VAL
9
12
1.55
18
B
B
O
H
CYS
GLU
19
21
1.54
18
B
B
O
H
VAL
TYR
12
16
1.55
20
B
B
O
H
VAL
TYR
12
16
1.43
20
B
B
O
H
SER
VAL
9
12
1.54
1
B
ARG
22
0.317
SIDE CHAIN
2
B
ARG
22
0.300
SIDE CHAIN
3
B
ARG
22
0.289
SIDE CHAIN
4
B
ARG
22
0.276
SIDE CHAIN
5
B
ARG
22
0.275
SIDE CHAIN
6
B
ARG
22
0.300
SIDE CHAIN
7
B
ARG
22
0.316
SIDE CHAIN
8
B
ARG
22
0.184
SIDE CHAIN
9
B
ARG
22
0.229
SIDE CHAIN
10
B
ARG
22
0.148
SIDE CHAIN
11
B
ARG
22
0.152
SIDE CHAIN
12
B
ARG
22
0.304
SIDE CHAIN
13
B
ARG
22
0.211
SIDE CHAIN
14
B
ARG
22
0.219
SIDE CHAIN
15
B
ARG
22
0.272
SIDE CHAIN
16
B
ARG
22
0.316
SIDE CHAIN
17
B
ARG
22
0.225
SIDE CHAIN
18
B
ARG
22
0.176
SIDE CHAIN
20
B
ARG
22
0.276
SIDE CHAIN
1
A
GLN
5
-143.77
-30.89
1
A
CYS
7
-100.99
-78.21
1
A
SER
9
-100.59
-161.33
1
A
CYS
11
-106.56
-164.62
1
B
VAL
2
-79.44
-159.94
1
B
PHE
24
159.32
143.59
1
B
THR
27
-91.88
-123.16
2
A
GLU
4
-81.22
-151.10
2
A
GLN
5
69.78
127.28
2
B
VAL
2
-161.63
-160.22
2
B
HIS
5
-165.37
109.14
2
B
ARG
22
159.95
-28.70
2
B
PHE
24
174.48
118.41
2
B
PHE
25
-109.50
78.28
2
B
TYR
26
165.86
112.03
2
B
PRO
29
-77.74
-161.80
3
A
GLU
4
-163.82
29.84
3
A
GLN
5
-46.41
163.01
3
A
SER
9
-108.97
-144.68
3
A
CYS
11
-108.04
-168.31
3
A
CYS
20
-55.86
-173.83
3
B
VAL
2
-94.51
-159.55
3
B
ASN
3
51.18
80.62
3
B
GLU
21
173.27
-49.52
3
B
PHE
24
-177.87
118.01
3
B
THR
27
-154.69
17.59
3
B
LYS
28
72.06
65.26
4
A
GLU
4
163.34
160.20
4
A
CYS
6
161.51
-23.34
4
A
THR
8
83.45
1.70
4
A
SER
9
-116.07
-141.52
4
A
ILE
10
-145.72
-42.67
4
A
CYS
11
39.95
-167.32
4
A
CYS
20
-67.21
-174.56
4
B
VAL
2
-92.63
-159.73
4
B
LEU
6
-118.80
-165.13
4
B
CYS
7
173.57
-54.87
4
B
CYS
19
-93.76
-67.33
4
B
GLU
21
172.27
96.89
4
B
ARG
22
177.55
-34.01
4
B
PRO
29
-78.68
-87.69
5
A
GLU
4
-133.18
-153.18
5
A
CYS
7
-76.12
-74.42
5
A
CYS
11
-166.99
-168.66
5
B
VAL
2
-80.14
-152.47
5
B
ASN
3
-30.77
115.33
5
B
SER
9
-39.26
-36.33
5
B
ARG
22
174.05
-31.69
6
A
GLU
4
-171.50
70.95
6
A
SER
9
-91.73
-147.72
6
A
ILE
10
-132.35
-34.32
6
A
CYS
11
66.21
-161.30
6
B
VAL
2
-160.26
-163.27
6
B
ASN
3
-65.40
94.67
6
B
CYS
7
-143.83
-39.38
6
B
CYS
19
-98.56
-68.90
6
B
ARG
22
-173.23
-36.71
6
B
PHE
24
177.16
155.27
6
B
PHE
25
-139.80
-79.75
6
B
TYR
26
50.03
177.45
6
B
LYS
28
53.05
106.90
6
B
PRO
29
-77.50
-162.79
7
A
CYS
6
56.84
16.43
7
A
SER
9
-102.75
-168.32
7
A
CYS
11
38.23
-164.73
7
A
CYS
20
-69.57
-171.62
7
B
VAL
2
-144.46
-151.13
7
B
CYS
7
-146.48
-47.65
7
B
ARG
22
174.13
-32.40
7
B
LYS
28
-169.11
-61.44
8
A
GLN
5
78.55
-71.43
8
A
CYS
6
-150.47
32.14
8
A
SER
9
-147.88
-157.16
8
A
CYS
20
-68.13
-171.42
8
B
VAL
2
-108.40
-160.65
8
B
ASN
3
-45.70
161.60
8
B
CYS
19
-75.87
-70.67
8
B
GLU
21
-172.24
-90.08
8
B
THR
27
-160.02
94.35
8
B
LYS
28
64.11
110.75
8
B
PRO
29
-78.64
-165.50
9
A
GLU
4
-175.37
-67.15
9
A
GLN
5
68.20
-72.32
9
A
CYS
6
-147.37
29.29
9
A
CYS
11
52.22
-177.24
9
B
VAL
2
-160.83
-166.79
9
B
GLU
21
175.99
-64.47
9
B
PHE
24
165.44
144.04
9
B
PHE
25
-140.30
-97.38
9
B
TYR
26
55.91
94.59
9
B
LYS
28
169.80
133.34
10
A
GLU
4
59.97
119.92
10
A
GLN
5
-150.60
-44.81
10
A
CYS
6
-158.92
38.72
10
A
SER
9
-121.99
-147.70
10
A
ILE
10
-128.48
-63.28
10
A
CYS
11
66.70
179.13
10
B
VAL
2
-100.18
-159.45
10
B
GLN
4
-105.13
53.03
10
B
SER
9
-46.42
-75.16
10
B
CYS
19
-101.69
-66.00
10
B
GLU
21
156.62
52.98
10
B
ARG
22
-146.76
13.17
10
B
PRO
29
-76.59
-82.47
11
A
GLU
4
177.37
145.68
11
A
CYS
11
50.44
-170.74
11
A
CYS
20
-104.45
-167.44
11
B
CYS
7
-143.39
-39.06
11
B
GLU
21
175.53
-68.76
11
B
PHE
24
157.42
131.40
12
A
SER
9
-104.23
-151.40
12
B
ASN
3
63.50
110.54
12
B
SER
9
-39.63
-75.08
12
B
ARG
22
-172.57
-34.23
12
B
PHE
24
-177.91
128.09
12
B
TYR
26
165.04
111.08
12
B
THR
27
-131.47
-147.98
12
B
PRO
29
-77.17
-93.05
13
A
GLU
4
-98.25
-90.64
13
A
GLN
5
-131.30
-86.41
13
A
CYS
7
-116.28
-71.56
13
A
CYS
11
-109.85
-164.85
13
A
CYS
20
-107.18
-165.64
13
B
GLU
21
58.54
108.65
13
B
ARG
22
158.27
-25.28
13
B
PHE
24
42.08
91.07
13
B
THR
27
-106.92
-145.82
13
B
PRO
29
-78.96
-166.22
14
A
GLU
4
-147.91
19.85
14
A
CYS
6
-162.56
35.69
14
A
SER
9
-123.86
-128.10
14
A
CYS
20
-70.39
-167.37
14
B
CYS
7
-121.60
-158.59
14
B
CYS
19
-96.98
-61.68
14
B
GLU
21
178.89
-56.91
14
B
PHE
24
58.36
117.24
14
B
LYS
28
172.40
-49.46
15
A
GLU
4
179.52
40.53
15
A
SER
9
-102.28
-150.27
15
A
ILE
10
-132.19
-31.47
15
A
CYS
11
56.70
-174.89
15
A
CYS
20
-61.27
-168.10
15
B
ASN
3
33.80
71.35
15
B
CYS
7
-140.63
-44.92
15
B
CYS
19
-88.70
-70.61
15
B
GLU
21
-176.25
-76.42
15
B
PHE
24
165.51
141.19
16
A
GLU
4
-93.62
-66.97
16
A
GLN
5
80.38
-13.46
16
A
CYS
7
-130.77
-36.43
16
A
THR
8
-76.20
-80.26
16
A
SER
9
-72.51
-133.00
16
A
CYS
11
-48.81
-177.94
16
B
ASN
3
160.11
-159.70
16
B
GLN
4
-77.83
-163.72
16
B
CYS
7
-150.90
12.36
16
B
ARG
22
171.67
-33.99
16
B
PHE
24
-170.66
113.56
16
B
LYS
28
164.61
-49.71
16
B
PRO
29
-76.08
-93.50
17
A
SER
9
-67.73
-157.63
17
A
CYS
11
-59.88
-152.96
17
B
VAL
2
-152.13
-151.17
17
B
ASN
3
-147.87
55.34
17
B
GLU
21
54.43
105.75
17
B
ARG
22
175.09
-29.61
17
B
THR
27
-152.66
-135.37
17
B
PRO
29
-78.07
-85.59
18
A
GLN
5
-159.72
-96.44
18
A
THR
8
47.73
24.75
18
A
SER
9
-151.98
-147.76
18
A
ILE
10
-140.59
-49.96
18
A
CYS
11
45.15
-175.43
18
B
VAL
2
-134.63
-159.85
18
B
GLU
21
175.37
-35.29
18
B
TYR
26
177.24
168.44
18
B
THR
27
-108.48
-102.02
18
B
LYS
28
-169.87
100.15
19
A
GLU
4
-137.41
-90.08
19
A
GLN
5
81.44
-47.41
19
A
CYS
7
-102.36
-66.55
19
A
CYS
11
38.24
-165.27
19
B
VAL
2
-161.46
-152.51
19
B
ASN
3
-36.75
135.46
19
B
GLU
21
-119.77
64.58
19
B
PHE
24
-38.38
140.53
20
A
CYS
20
-100.58
-165.56
20
B
VAL
2
-118.41
-159.88
20
B
CYS
19
-102.69
-63.67
20
B
ARG
22
165.91
-34.14
NMR STRUCTURE OF HUMAN INSULIN MUTANT ILE-A2-GLY, VAL-A3-GLY, HIS-B10-ASP, PRO-B28-LYS, LYS-B29-PRO, 20 STRUCTURES
1
N
N
2
N
N
A
LEU
13
A
LEU
13
HELX_P
A
TYR
19
A
TYR
19
1
1
7
B
SER
9
B
SER
9
HELX_P
B
CYS
19
B
CYS
19
1
2
11
disulf
2.020
A
CYS
6
A
SG
CYS
6
1_555
A
CYS
11
A
SG
CYS
11
1_555
disulf
2.020
A
CYS
7
A
SG
CYS
7
1_555
B
CYS
7
B
SG
CYS
7
1_555
disulf
2.018
A
CYS
20
A
SG
CYS
20
1_555
B
CYS
19
B
SG
CYS
19
1_555
HORMONE/GROWTH FACTOR
HORMONE, HUMAN INSULIN, MUTANT, HORMONE-GROWTH FACTOR COMPLEX
INS_HUMAN
UNP
1
90
P01308
GIVEQCCTSICSLYQLENYCN
INS_HUMAN
UNP
2
25
P01308
FVNQHLCGSHLVEALYLVCGERGFFYTPKT
90
110
1LKQ
1
21
P01308
A
1
1
21
25
54
1LKQ
1
30
P01308
B
2
1
30
1
ILE
engineered mutation
GLY
2
1LKQ
A
P01308
UNP
91
2
1
VAL
engineered mutation
GLY
3
1LKQ
A
P01308
UNP
92
3
2
HIS
engineered mutation
ASP
10
1LKQ
B
P01308
UNP
34
10
2
PRO
engineered mutation
LYS
28
1LKQ
B
P01308
UNP
52
28
2
LYS
engineered mutation
PRO
29
1LKQ
B
P01308
UNP
53
29
1
P 1